ContraFect promotes Steven C. Gilman to permanent CEO
Dr. Gilman has served as Interim Chief Executive Officer since March 21, 2016. He will continue to serve as Chairman of the Board of Directors of the Company.
Dr. Gilman served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co.
Prior to joining Cubist in 2008, he served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics.
Previously, Dr. Gilman worked at Millennium Pharmaceuticals where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation franchise, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization.
Prior to Millennium, Dr. Gilman was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.
He has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College.
Dr. Gilman currently serves on the board of directors of publicly traded companies Keryx Biopharmaceuticals, Momenta Pharmaceuticals, SCYNEXIS, and Vericel Corporation, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board.
Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. He has authored over 60 publications and is an inventor on 7 patents. ■
LATEST MOVES FROM New York
- Wecast Network appoints Simon Wang as CFO
- Sequential Brands Group appoints Karen Murray as CEO
- Viacom appoints Kern Schireson as executive vice president
- S&P Global appoints Marco Alverà to board
- AIG CEO Peter D. Hancock to resign
More inside POST